Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.58 |
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.58 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.54 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.54 |
| ▸ | GRM8 | O00222 | 1/20 | 0.53 |
| ▸ | GRM6 | O15303 | 1/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.53 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30099715 | 1.00 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL29710629 | 1.00 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL30099611 | 1.00 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL14490692 | 1.00 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL11886061 | 1.00 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL9450867 | 1.00 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL20739235 | 1.00 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL22111146 | 1.00 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL20739236 | 1.00 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL30099588 | 1.00 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102249-A1 | TNF RECEPTOR SUPERFAMILY AGONIST FUSION POLYPEPTIDES | ANKYRA THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-12569577-B2 | PSMA-targeting imaging agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-10 | — | — | US | claimed |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | BOEHRINGER INGELHEIM INT GMH (DE) | 2025-12-18 | — | — | US | claimed |
| US-12343322-B2 | Composition and method for treating or prophylaxis of coronavirus and cancers | BETAHEALTH LLC (US) | 2025-07-01 | — | — | US | claimed |
| US-12336975-B2 | Composition and methods for treatment or prophylaxis of coronavirus and cancers | BETAHEALTH LLC (US) | 2025-06-24 | — | — | US | claimed |
| US-20250123280-A1 | LABEL-FREE DETECTION OF PROTEASE ACTIVITY | UNIV OREGON HEALTH & SCIENCE (US) | 2025-04-17 | — | — | US | claimed |
| CN-113343712-B | Social text emotion tendency analysis method and system based on heterogeneous graphs | 安徽大学 | 2025-03-14 | — | — | CN | claimed |
| WO-2025043563-A1 | PEPTIDE TARGETING SOMATOSTATIN RECEPTOR, DRUG CONJUGATE AND USE THEREOF | 主流源生物科技(上海)有限公司 | 2025-03-06 | — | — | WO | claimed |
| CN-118422409-A | Processing technology of yarn-pressing knitted fabric and product thereof | 泉州汇成针织有限公司 | 2024-08-02 | — | — | CN | claimed |
| US-20240247080-A1 | GLP1/GIP/NPY2 RECEPTOR TRIPLE AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-07-25 | — | — | US | claimed |
| CN-115884792-A | Targeted poly (beta-amino esters) | 艾夏卡法国有限公司 | 2023-03-31 | — | — | CN | claimed |
| US-11613753-B2 | Methods and pharmaceutical compositions for treating tubulin carboxypeptidases associated diseases | LES LABORATOIRES SERVIER (FR) | 2023-03-28 | — | — | US | claimed |
| WO-2023003984-A2 | LABEL-FREE DETECTION OF PROTEASE ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-01-26 | — | — | WO | claimed |
| US-20230016265-A1 | PSMA-TARGETING IMAGING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2023-01-19 | — | — | US | claimed |
| WO-2022266356-A1 | PEST AND PATHOGEN RESISTANCE IN PLANTS | J.R. SIMPLOT COMPANY (US) | 2022-12-22 | — | — | WO | claimed |
| CN-114958797-A | Mutant DNA polymerase, coding gene, recombinant expression vector, recombinant bacterium and application thereof | 郑州思昆生物工程有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114184726-A | Mass spectrum library of platycodin and construction method and application thereof | 南京中医药大学 | 2022-03-15 | — | — | CN | claimed |
| WO-2022046960-A1 | COMPOSITION AND METHODS FOR TREATMENT OR PROPHYLAXIS OF CORONAVIRUS AND CANCERS | BETAHEALTH, LLC (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220062219-A1 | COMPOSITION AND METHOD FOR TREATING OR PROPHYLAXIS OF CORONAVIRUS AND CANCERS | BETAHEALTH, LLC | 2022-03-03 | — | — | US | claimed |
| CN-113956348-A | Glucagon and GLP-1 co-agonist compounds | 伊莱利利公司 | 2022-01-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569577-B2 | PSMA-targeting imaging agents | FOLH1, PSMA2, PSMA1 | FOLH1 1/4885NAALAD2 142/4885RIMKLA 180/4885 |
| US-12343322-B2 | Composition and method for treating or prophylaxis of coronavirus and cancers | ACE2, RNASE1, MUC1 | FOLH1 337/4885NAALAD2 1729/4885RIMKLA 3336/4885 |
| US-12336975-B2 | Composition and methods for treatment or prophylaxis of coronavirus and cancers | ACE2, MUC1, RNASE1 | FOLH1 324/4885NAALAD2 1821/4885RIMKLA 3203/4885 |
| US-20220062219-A1 | COMPOSITION AND METHOD FOR TREATING OR PROPHYLAXIS OF CORONAVIRUS AND CANCERS | ACE2, RNASE1, MUC1 | FOLH1 337/4885NAALAD2 1729/4885RIMKLA 3336/4885 |
| US-20240247080-A1 | GLP1/GIP/NPY2 RECEPTOR TRIPLE AGONISTS | GLP1R, GIPR, NPY1R | FOLH1 1020/4885NAALAD2 1133/4885RIMKLA 2623/4885 |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | GLP1R, GIPR, NPY1R | FOLH1 479/4885NAALAD2 2432/4885RIMKLA 2569/4885 |
| US-20230016265-A1 | PSMA-TARGETING IMAGING AGENTS | FOLH1, PSMA1, PSMA2 | FOLH1 1/4885NAALAD2 92/4885RIMKLA 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.